• Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed FLT3-ITD positive AML

Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in China.

Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while Innovent Biologics holds sole commercialization rights for Vanflyta^® in China, leading market promotion.

VANFLYTA was approved in China in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an adequate validated diagnostic test, based on the results from the QuANTUM-First trial¹.

"This collaboration with Daiichi Sankyo represents an exciting milestone for our hematology franchise. Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence including TYVYT^® (sintilimab injection), HALPRYZA^® (rituximab injection), olverembatinib, FUCASO^® (Equecabtagene Autoleucel Injection), Jaypirca^® (pirtobrutinib), and the addition of VANFLYTA^® will further enhance our synergistic offerings," said Vivian Zhang, Executive Director, Chief Commercial Officer, Innovent Biologics. "Vanflyta^® (quizartinib) will be the 20th product in Innovent's commercialized product portfolio. Through collaborative efforts, we aim to bring forward innovative medicines to benefit patients with cancer and further strengthen our leadership in oncology."

"The partnership with Innovent Biologics reflects our commitment to delivering innovation to patients in China," said Michio Hayashi, China President, Daiichi Sankyo. "By combining our research and development capabilities with Innovent's commercial capabilities in China, we believe this collaboration can accelerate access to VANFLYTA^® for patients with newly diagnosed FLT3-ITD-positive AML and ultimately help improve outcomes in this high-risk patient population."